NG11-2 Phase Ib clinical trial
NG11-2 Phase-Ib Study Closes Enrolment – Results Expected Autumn 2024

A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer.

01st July 2024 VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, has now finished patient enrolment into both the Dose Escalation and Dose Expansion phases of their Phase-1b study, which uses NG11-2 mouthwash prior to each fractional radiotherapy dose to reduce and prevent severe Radiation-Induced Oral Mucositis (RIOM), a well-known and debilitating side-effect of radiotherapy on patients undergoing treatment for head & neck cancer.

A total of 15 patients with head and neck cancer have been successfully enrolled in this Phase-1b study with daily oral topical treatment of NG11-2 prior to each fractional radiation for up to 7 weeks. Following the Safety Committee’s assessment and agreement to use the highest dose in the Dose Expansion phase, a total of 9 patients have been enrolled and treated at this highest dose level.

The final patient visits for follow-up will take place over the summer with a view to close the study and report the final outcome in autumn this year.

Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:

“We are delighted to announce the completion of enrolment in this important study and look forward to the final results later this year. The readout of this study will define the Recommended Phase 2 Dose for moving onto the next stage of clinical development of this exciting treatment. The VasoDynamics team would like to thank all the participating clinical sites for their excellent support to help meet this important milestone within the planned timeline.”

For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO +44 7969132263
Gary Bower, COO +44 7960388412

Notes to Editors:

About VasoDynamics

VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.